Cytokine Release Syndrome Stratification

Solutions Accelerated by IsoPlexis

  • Cytokine Release Syndrome Prediction

Apply PSI to inflammation of CAR T-cell product correlates to Grade 3+ CRS, pre-infusion1

Uncover the polyfunctional immune cell subsets which correlate to IRAEs in immunotherapy and discover biomarker correlates to inflammation.

Download EBook

Research Area

Development Stage

Predict

Goal

Preinfusion prediction of in vivo CRS in CAR-T patients, not possible with legacy technologies

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell

Solution

IsoPlexis’ PSI is able to stratify severe CRS occurrence in CAR-T patients

polyfunctional cell

Finding

PSI of the pre-infusion CAR-T product was found to associate with in vivo CRS

follow our data

Follow Our Data

See the latest published data in Inflammatory & Autoimmune Disease

Higher CAR-T product PSI was found to statistically associate with grade 3+ CRS (p = 0.0174). PSI was measured across CD4+ and CD8+ samples from 20 patients.

In particular, there were large increases in the production of effector and stimulatory cytokines in the 3+ CRS cohort. These results suggest that the combination of frequency and cytokine production levels of polyfunctional T cells in the product associate with toxicity to treatment with CAR-T cells.1

Download EBook
PSI Association with CRS

Solution

Detect Critical Differences

In vitro single CD14+ MO PSI differences between MS patient groups with no treatment, versus treated with Tysabri. LPS-stimulated samples show significant upregulation in polyfunctional cytokine signal between untreated MS patients (n=6) and Tysabri treated MS patients (n=3).

The CAR-T product PSI association with in vivo grade 3+ CRS was strengthened when the metric was combined with day 0 IL-15 levels in the patients (p = 0.085). IL-15 levels in the blood were measured by ELISA.1

IL-15 Day 0 + PSI

Request a Seminar

Request a Seminar
Discover IsoLight